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Abstract
Synthesis and cytotoxic activities of 32 benzhydrylpiperazine derivatives with carboxamide and
thioamide moieties were reported. In vitro cytotoxic activities of compounds were screened
against hepatocellular (HUH-7), breast (MCF-7) and colorectal (HCT-116) cancer cell lines by
sulphorhodamine B assay. In general, 4-chlorobenzhydrylpiperazine derivatives were more
cytotoxic than other compounds. In addition, thioamide derivatives (6a–g) have higher growth
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Introduction
Cancer is the disease resulting from abnormal cells with abilities
of uncontrolled dividing and invasion to other tissues through
blood and lymph systems. Recently advanced treatment opportu-
nities are unable to overcome the major problems of chemother-
apy such as drug resistance and severe side effects due to the lack
of specificity. Regarding issues lead the researchers to develop
varying drug-like compounds targeting cancer.
Piperazine-1-carboxamides have diverse actions such as antag-
onism of CB1, human CCR2 chemokine, androgen and vanilloid
receptors or inhibition of PDGFR phosphorylation1–5.
Benzhydrylpiperazine scaffold is well known for its antihista-
minic activity6–11. Furthermore calcium channel blocking12–19,
dopaminergic20–23, antimicrobial24–41 and antiviral42,43 activities
are often mentioned in literature.
Anticancer activity of benzhydrylpiperazines has recently
advanced44–51. Kumar et al. have performed cytotoxicity assays
to several 1-benzhydrylpiperazine derivatives substituted with
variable sulfonyl chlorides, acid chlorides and isothiocyanates.
These derivatives have potent cytotoxicity over breast cancer
(MCF-7), hepatocellular (HepG-2), cervix (HeLa) and colon
carcinoma (HT-29) cell lines44. Yarim et al., also performed
cytotoxicity screenings for some 4-chlorobenzhydrylpiperazines
substituted with variable benzoyl chloride derivatives and
reported their high activities against liver (HUH-7, FOCUS,
MAHLAVU, HepG-2, Hep-3B), breast (MCF-7, BT20, T47D,
CAMA-1), colon (HCT-116), gastric (KATO-3) and endometrial
(MFE-296) cancer cell lines45. In addition, our work group has
recently reported a study in which sulfonamide and benzamide
derivatives of benzhydrylpiperazines were discussed for their
cytotoxicities against HUH-7, MCF-7 and HCT-116 cancer cell
lines52.
In this study, we reported the synthesis, purification and
characterization of some novel compounds bearing benzhydrylpi-
perazine backbone. Those compounds were tested for their
cytotoxic activities against hepatocellular (HUH-7), breast
(MCF-7) and colorectal (HCT-116) cancer cell lines with
sulphorhodamine B (SRB) assay. We aimed to develop a structure
activity relationship for benzhydrylpiperazine derivatives in
accordance with their cytotoxic activity results.
Materials and methods
Chemistry
All chemicals and reagents used in the current study were of
analytical grade. The reactions were monitored by thin layer
chromatography (TLC) on Merck pre-coated silica GF254 plates
(Merck KGaA, Darmstadt, Germany). Melting points (C) of the
compounds were determined by using a Mettler Toledo FP62
capillary melting point apparatus (Mettler-Toledo, Greifensee,
Switzerland) and are uncorrected. Ultraviolet spectra were
recorded with Agilent 8453 UV-Visible Spectrophotometer
(Agilent Technologies, Santa Clara, CA). Infrared spectra were
recorded on a Perkin-Elmer Spectrum One series FT-IR apparatus
(Version 5.0.1, Perkin Elmer, Norwalk, CT), using potassium
bromide pellets, the frequencies were expressed in cm1. The 1H-
and 13C-NMR spectra were recorded with a Varian Mercury-400
FT-NMR spectrometer (Varian Inc., Palo Alto, CA), using
tetramethylsilane (TMS) as the internal reference, with dimethyl-
sulfoxide (DMSO-d6) as solvent, the chemical shifts were
reported in parts per million (ppm). Coupling constants were
recorded in Hertz (Hz). The mass spectra were recorded with a
Waters 2695 Alliance Micromass ZQ LC/MS instrument (Waters
Corp., Milford, MA). Elemental analyses were performed on
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LECO 932 CHNS (LECO-932, St. Joseph, MI) instrument and
were within 0.4% of the theoretical values.
General procedure for preparation of benzhydrole
derivatives
Ten millimoles (2.2 g) of benzophenone was dissolved in
10 ml of ethanol. In a separate flask, 11 mmol (0.4 g) of sodium
borohydride (NaBH4) was dissolved in 2 ml of ethanol. Sodium
borohydride solution was slowly added to benzophenone solu-
tion with a Pasteur pipette. Reaction mixture was allowed
to continue stirring for a further 30 min. For the work up of
reaction, 2 ml of concentrated HCl was added to a 20 ml ice-water
solution. Reaction mixture was poured into this ice cold
solution slowly with stirring. White solid product was collected
with vacuum filtration and washed twice with distilled water.
4-Chlorobenzophenone and 4,40-difluorobenzophenone were also
reacted with sodium borohydride to give 4-chlorobenzhydrole
and 4,40-difluorobenzhydrole, respectively, according to above
procedure.
General procedure for preparation of benzhydryl chloride
derivatives
Ten millimoles (1.84 g) of benzhydrole was added to 15 ml
of concentrated HCl. 10 mmol (1.1 g) of anhydrous calcium
chloride was added to the mixture to be refluxed at 85 C for 4 h
with stirring. After the reaction is completed, the flask was cooled
to room temperature and extracted twice with 20 ml of ethyl
acetate. Organic layers were combined together, washed with
brine and water, then dried over anhydrous sodium sulfate.
Followed by the concentration under vacuo, the product
was collected as brown liquid. 4-Chlorobenzhydryl chloride and
4,40-difluorobenzhydryl chloride were also synthesized from
4-chlorobenzhydrole and 4,40-difluorobenzhydrole according to
above procedure.
General procedure for preparation of
benzhydrylpiperazine derivatives
Nine millimoles (0.78 g) of piperazine was dissolved in
dimethylformamide. Anhydrous potassium carbonate was added
to the solution and stirred for 10 min. Followed by the addition of
9 mmol (1.82 g) of benzhydryl chloride, reaction mixture was
heated at 80 C for 8 h. After completion, dimethylformamide
was removed under vacuo, then the residue was taken in water
and extracted with ethyl acetate. Organic layer was washed with
water and dried over anhydrous sodium sulfate. The solvent
was evaporated and white solid product was obtained. 1-[(4-
Chlorophenyl)(phenyl)methyl]piperazine and 4,40-benzhydrylpi-
perazine were also synthesized from 4-chlorobenzhydryl chloride
and 4,40-difluorobenzhydryl chloride consecutively according to
above procedure.
General procedure for preparation of N-alkyl-4-
[benzhydryl/4-chlorobenzhydryl/4,40-
difluorobenzhydryl]piperazine-1-carboxamides
Two millimoles (0.515 g) of 1-benzhydrylpiperazine or 1.7 mmol
(0.515 g) of 1-(4,40-difluorobenzhydryl)piperazine or 0.872 mmol
(0.2632 g) of 1-(4-chlorobenzhydryl)piperazine was dissolved in
20 mL of dry dichloromethane. Reaction flask was taken into ice
bath and triethylamine (1:3 moles) was added to the solution. Ice
bath was removed after 10 min and appropriate isocyanate
derivative (1:1 mole) was added. Reaction was mixed overnight
at room temperature. After the reaction is completed, solution was
extracted with water and ammonium chloride solution (10%),
respectively. Dichloromethane layer was washed with water again
and dried with anhydrous sodium sulfate. Solvent was evaporated




White, opaque, needle-shaped crystals, 68% (0.240 g), m.p.
198.4 C. UV (MeOH, max, nm); 205 (log ": 5.17), 224 (log ":
4.69). FT-IR (KBr, cm1); 3342 (N–H), 3022 (C–H, aromatic),
2959 (C–H, aliphatic), 1619 (C¼O, amide), 1540 (C¼C,
aromatic), 1246 (C–N). 1H-NMR (DMSO, ppm); 0.78 (t, 3H,
–CH2–CH3, J¼ 7.6 Hz); 0.98 (d, 3H, –CH–CH3, J¼ 6.8 Hz); 1.35
(m, 2H, –CH2–CH3); 2.23 (t, 4H, piperazine H3, H5, J¼ 4.8 Hz);
3.28 (t, 4H, piperazine H2, H6, J¼ 4.8 Hz); 3.53 (m, 1H, –NH–
CH–); 4.29 (s, 1H, (Ar)2CH–); 6.02 (d, 1H, –CONH–, J¼ 7.6 Hz);
7.20 (m, 2H, diphenyl H4, H40); 7.30 (t, 4H, diphenyl H3, H5, H30,
H50, J¼ 7.6 Hz); 7.43 (t, 4H, diphenyl H2, H6, H20, H60,
J¼ 7.2 Hz). 13C-NMR (DMSO, ppm); 11.43 (C21); 21.45 (C22);
29.90 (C20); 44.25 (C14,16); 47.82 (C19); 52.06 (C15,17); 75.59
(C7); 127.56 (C4,11); 128.29 (C2,6,9,13); 129.20 (C3,5,10,12); 143.30
(C1,8); 157.76 (C18). MS (m/z); 352.8 (M
þ); 253.7 ((C6H5)2
CHN(C2H4)2NHeþ); 167.5 ((C6H5)2CHeþ). Elemental analysis of
C22H29N3O (MW: 351.49 g/mol); C 75.18, H 8.32, N 11.96
(Calcd.); C 75.12, H 8.27, N 11.85 (Found).
N-tert-Butyl-4-(diphenylmethyl)piperazine-1-carboxamide (5b)
White, opaque, needle-shaped crystals, 62% (0.436 g), m.p.
192.4 C. UV (MeOH, max, nm); 206 (log ": 5.13), 227 (log ":
4.62). FT-IR (KBr, cm1); 3322 (N–H), 3023 (C–H, aromatic),
2970 (C–H, aliphatic), 1621 (C¼O, amide), 1536 (C¼C,
aromatic), 1260 (C–N). 1H-NMR (DMSO, ppm); 1.22 (s, 9H,
–C(CH3)3); 2.23 (t, 4H, piperazine H3, H5, J¼ 4.8 Hz); 3.25
(t, 4H, piperazine H2, H6, J¼ 4.4 Hz); 4.29 (s, 1H, (Ar)2CH–);
5.68 (s, 1H, CONH); 7.19 (m, 2H, diphenyl H4, H40); 7.30 (t, 4H,
diphenyl H3, H5, H30, H50, J¼ 7.6 Hz); 7.43 (t, 4H, diphenyl H2,
H6, H20, H60, J¼ 7.2 Hz). Elemental analysis of C22H29N3O (MW:
351.49 g/mol); C 75.18, H 8.32, N 11.96 (Calcd.); C 74.60,
H 8.21, N 11.84 (Found).
N-Isopropyl-4-(diphenylmethyl)piperazine-1-carboxamide (5c)
White, opaque, clustered crystals, 94% (0.318 g), m.p. 220.4 C.
UV (MeOH, max, nm); 207 (log ": 5.21), 227 (log ": 4.81). FT-IR
(KBr, cm1); 3367 (N–H), 3060 (C–H, aromatic), 2964 (C–H,
aliphatic), 1611 (C¼O, amide), 1538 (C¼C, aromatic), 1254
(C–N). 1H-NMR (DMSO, ppm); 0.98 (d, 6H, –CH(CH3)2,
J¼ 6.8 Hz); 2.19 (t, 4H, piperazine H3, H5, J¼ 4.8 Hz); 3.25
(t, 4H, piperazine H2, H6, J¼ 5.2 Hz); 3.68 (m, 1H, –CH(CH3)2);
4.25 (s, 1H, (Ar)2CH–); 6.05 (d, 1H, CONH, J¼ 7.6 Hz); 7.15
(m, 2H, diphenyl H4, H40); 7.26 (t, 4H, diphenyl H3, H5, H30,
H50, J¼ 7.2 Hz); 7.39 (t, 4H, diphenyl H2, H6, H20, H60,
J¼ 6.8 Hz). Elemental analysis of C21H27N3O (MW: 337.46 g/
mol); C 74.74, H 8.06, N 12.45 (Calcd.); C 74.89, H 7.73, N 12.30
(Found).
N-Ethyl-4-(diphenylmethyl)piperazine-1-carboxamide (5d)
White, shiny, flat crystals, 84% (0.294 g), m.p. 208.9 C. UV
(MeOH, max, nm); 203 (log ": 5.11), 221 (log ": 4.58). FT-IR
(KBr, cm1); 3365 (N–H), 3024 (C–H, aromatic), 2978 (C–H,
aliphatic), 1622 (C¼O, amide), 1545 (C¼C, aromatic), 1259
(C–N).1H-NMR (DMSO, ppm); 0.98 (t, 3H, –CH3, J¼ 7.6 Hz);
2.23 (t, 4H, piperazine H3, H5, J¼ 4.8 Hz); 3.01 (m, 2H, –CH2–);
3.28 (t, 4H, piperazine H2, H6, J¼ 5.2 Hz); 4.28 (s, 1H,
(Ar)2CH–); 6.41 (t, 1H, CONH, J¼ 5.2 Hz); 7.20 (m, 2H,
diphenyl H4, H40); 7.29 (t, 4H, diphenyl H3, H5, H30, H50,































J¼ 8 Hz); 7.43 (t, 4H, diphenyl H2, H6, H20, H60, J¼ 7.2 Hz).
Elemental analysis of C22H29N3O (MW: 351.49 g/mol); C 74.27,
H 7.79, N 12.99 (Calcd.); C 73.77, H 7.46, N 12.93 (Found).
N-(2,6-Dichlorophenyl)-4-(diphenylmethyl)piperazine-1-
carboxamide (5e)
White, opaque, powdered crystals, 88% (0.386 g), m.p. 234.6 C.
UV (MeOH, max, nm); 207 (log ": 5.32), 226 (log ": 4.72). FT-IR
(KBr, cm1); 3237 (N–H,), 3025 (C–H, aromatic), 2967 (C–H,
aliphatic), 1638 (C¼O, amide), 1528 (C¼C, aromatic), 1255
(C–N). 1H-NMR (DMSO, ppm); 2.29 (t, 4H, piperazine H3, H5,
J¼ 4.8 Hz); 3.44 (t, 4H, piperazine H2, H6, J¼ 4 Hz); 4.33 (s, 1H,
(Ar)2CH–); 7.15–7.3 (m, 10H, diphenyl); 7.40–7.47 (m, 3H, 2,6-
dichlorophenyl); 8.34 (s, 1H, CONH). Elemental analysis of
C24H23Cl2N3O (MW: 440.36 g/mol); C 65.46, H 5.26, N 9.54
(Calcd.); C 65.37, H 5.36, N 9.62 (Found).
N-(2-Benzylphenyl)-4-(diphenylmethyl)piperazine-1-
carboxamide (5f)
White, opaque, feather-like crystals, 89% (0.412 g), m.p. 192.1 C.
UV (MeOH, max, nm); 203 (log ": 5.12), 224 (log ": 4.26). FT-IR
(KBr, cm1); 3251 (N–H), 3060 (C–H, aromatic), 2954 (C–H,
aliphatic), 1637 (C¼O, amide), 1524 (C¼C, aromatic), 1253
(C–N). 1H-NMR (DMSO, ppm); 2.24 (t, 4H, piperazine H3, H5,
J¼ 4.8 Hz); 3.37 (t, 4H, piperazine H2, H6, J¼ 4.8 Hz); 3.91
(s, 2H, –CH2–); 4.29 (s, 1H, (Ar)2CH–); 7.05–7.25 (m, 10H,
diphenyl); 7.30 (m, 5H, phenyl); 7.44 (m, 4H, N-phenyl); 7.97
(s, 1H, CONH). Elemental analysis of C31H31N3O (MW:
461.60 g/mol); C 80.66, H 6.77, N 9.10 (Calcd.); C 80.90,
H 6.48, N 9.13 (Found).
Ethyl 2-[4-(diphenylmethyl)piperazino]carbamoyl]acetate
(5g, CAS No: 1350123-57-7)
White, opaque, powdered crystals, 69% (0.263 g), m.p. 150 C.
UV (MeOH, max, nm); 202 (log ": 4.87), 223 (log ": 4.35). FT-IR
(KBr, cm1); 3360 (N–H), 3026 (C–H, aromatic), 2986 (C–H,
aliphatic), 1755 (C¼O, ester), 1636 (C¼O, amide), 1531 (C¼C,
aromatic), 1192 (C–O), 1147 (C–N). 1H-NMR (DMSO, ppm);
1.17 (t, 3H, –CH2–CH3, J¼ 6.8 Hz); 2.25 (t, 4H, piperazine H3,
H5, J¼ 4.4 Hz); 3.31 (t, 4H, piperazine H2, H6, J¼ 4.8 Hz); 3.68
(d, 2H, –NH–CH2–, J¼ 5.6 Hz); 4.05 (q, 2H, –O–CH2–); 4.30
(s, 1H, (Ar)2CH–); 6.93 (t, 1H, CONH, J¼ 6 Hz); 7.19 (t, 2H,
diphenyl H4, H40, J¼ 7.2 Hz); 7.29 (t, 4H, diphenyl H3, H5,
H30, H50, J¼ 7.2 Hz); 7.44 (d, 4H, diphenyl H2, H6, H20,
H60, J¼ 7.6 Hz). Elemental analysis of C22H27N3O3 (MW:
381.47 g/mol); C 69.27, H 7.13, N 11.02 (Calcd.); C 69.24,
H 6.96, N 10.96 (Found).
N-Allyl-4-(diphenylmethyl)piperazine-1-carboxamide (5h, CAS
No: 1349487-56-4)
White, shiny, flat crystals, 96% (0.323 g), m.p. 213.6 C. UV
(MeOH, max, nm); 207 (log ": 5.32), 226 (log ": 4.75). FT-IR
(KBr, cm1); 3343 (N–H), 3027 (C–H, aromatic), 2954 (C–H,
aliphatic), 1625 (C¼O, amide), 1546 (C¼C, aromatic), 1255
(C–N). 1H-NMR (DMSO, ppm); 2.23 (t, 4H, piperazine H3, H5,
J¼ 4.8 Hz); 3.30 (t, 4H, piperazine H2, H6, J¼ 4.8 Hz); 3.63
(t, 2H, –CH2–, J¼ 5.2 Hz); 4.29 (s, 1H, (Ar)2CH-); 5.0 (dd, 2H,
–CH¼CH2, J1¼17.2 Hz, J2¼ 8 Hz, J3¼ 1.6 Hz); 5.78 (m, 1H,
–CH¼CH2); 6.61 (t, 1H, CONH, J¼ 5.2 Hz); 7.17 (t, 2H,
diphenyl H4, H40, J¼ 7.6 Hz); 7.29 (t, 4H, diphenyl H3, H5, H30,
H50, J¼ 7.6 Hz); 7.43 (d, 4H, diphenyl H2, H6, H20, H60,
J¼ 8.8 Hz). Elemental analysis of C21H25N3O (MW:
335.44 g/mol); C 75.19, H 7.51, N 12.53 (Calcd.); C 75.09, H
7.25, N 12.46 (Found).
N-sec-Butyl-4-[bis(4-fluorophenyl)methyl]piperazine-1-
carboxamide (5i)
White, opaque, powdered crystals, 54% (0.208 g), m.p. 157.7 C.
UV (MeOH, max, nm); 207 (log ": 5.24), 225 (log ": 4.71). FT-IR
(KBr, cm1); 3310 (N–H), 3076 (C–H, aromatic), 2965 (C–H,
aliphatic), 1615 (C¼O, amide), 1548 (C¼C, aromatic), 1247
(C–N), 1223 (C–F). 1H-NMR (DMSO, ppm); 0.8 (t, 3H,
–CH2CH3, J¼ 7.2 Hz); 0.98 (d, 3H, –CH–CH3, J¼ 6.8 Hz);
2.24 (t, 4H, piperazine H3, H5, J¼ 4.8 Hz); 2.5 (m, 2H, –CH–
CH2–CH3); 3.28 (t, 4H, piperazine H2, H6, J¼ 4.8 Hz); 3.54 (m,
1H, –NH–CH–); 4.38 (s, 1H, (Ar)2CH–); 6.04 (d, 1H, CONH,
J¼ 7.6 Hz); 7.10–7.16 (m, 4H, diphenyl H2, H6, H20, H60); 7.41–
7.45 (m, 4H, diphenyl H3, H5, H30, H50). MS (m/z); 388.95 (M
þ);
290.00 ((4-F-C6H5)2CH[N(C2H4)2N]Heþ); 203.5 (100%, (4-F-
C6H5)2CHeþ). Elemental analysis of C22H27F2N3O (MW:
387.46 g/mol); C 68.20, H 7.02, N 10.84 (Calcd.); C 67.44,
H 7.01, N 10.89 (Found).
N-tert-Butyl-4-[bis(4-fluorophenyl)methyl]piperazine-1-carboxa-
mide (5j)
White, opaque, feather-like crystals, 82% (0.317 g), m.p. 162.4 C.
UV (MeOH, max, nm); 208 (log ": 5.32), 227 (log ": 4.78). FT-IR
(KBr, cm1); 3332 (N–H), 3046 (C–H, aromatic), 2968 (C–H,
aliphatic), 1623 (C¼O, amide), 1537 (C¼C, aromatic), 1259
(C–N), 1219 (C–F). 1H-NMR (DMSO, ppm); 1.22 (s, 9H,
C(CH3)3); 2.20 (t, 4H, piperazine H3, H5, J¼ 4.8 Hz); 3.24
(t, 4H, piperazine H2, H6, J¼ 4.8 Hz); 4.38 (s, 1H, (Ar)2CH–);
5.68 (s, 1H, CONH); 7.10–7.16 (m, 4H, diphenyl H2, H6, H20,
H60); 7.41–7.45 (m, 4H, diphenyl H3, H5, H30, H50). MS (m/z);
388.88 (100%, Mþ); 203.51 ((4-F-C6H5)2CHeþ). Elemental
analysis of C22H27F2N3O (MW: 387.46 g/mol); C 68.20, H 7.02,
N 10.84 (Calcd.); C 67.96, H 7.32, N 10.87 (Found).
N-Butyl-4-[bis(4-fluorophenyl)methyl]piperazine-1-
carboxamide (5k)
White, opaque, flat crystals, 45% (0.174 g), m.p. 132.9 C. UV
(MeOH, max, nm); 209 (log ": 5.43), 226 (log ": 4.83). FT-IR
(KBr, cm1); 3402 (N–H), 3073 (C–H, aromatic), 2962 (C–H,
aliphatic), 1629 (C¼O, amide), 1531 (C¼C, aromatic), 1251
(C–N), 1217 (C–F). 1H-NMR (DMSO, ppm); 0.85 (t, 3H, –CH3,
J¼ 7.2 Hz) 1.20-1.27 (m, 2H, –CH2–CH3); 1.31–1.37 (m, 4H,
–CH2CH2CH3–); 2.21 (t, 4H, piperazine H3, H5, J¼ 4.4 Hz);
2.95–3.06 (q, 2H, –NH–CH2–); 3.27 (t, 4H, piperazine H2, H6,
J¼ 5.2 Hz); 4.38 (s, 1H, (Ar)2CH–); 6.38 (t, 1H, CONH); 7.1–
7.15 (m, 4H, diphenyl H2, H6, H20, H60); 7.41–7.45 (m, 4H,
diphenyl H3, H5, H30, H50). MS (m/z); 388.93 (100%, M
þ); 203.55
((4-F-C6H5)2CHeþ). Elemental analysis of C22H27F2N3O (MW:
387.46 g/mol); C 68.20, H 7.02, N 10.84 (Calcd.); C 67.92,
H 6.82, N 10.85 (Found).
N-Ethyl-4-[bis(4-fluorophenyl)methyl]piperazine-1-
carboxamide (5l)
White, opaque, cotton-like crystals, 83% (0.297 g), m.p. 175 C.
UV (MeOH, max, nm); 207 (log ": 5.39), 225 (log ": 4.81). FT-IR
(KBr, cm1); 3349 (N–H), 3060 (C–H, aromatic), 2972 (C–H,
aliphatic), 1617 (C¼O, amide), 1544 (C¼C, aromatic), 1253
(C–N), 1216 (C–F). 1H-NMR (DMSO, ppm); 0.98 (t, 3H, –CH3,
J¼ 6.8 Hz); 2.21 (t, 4H, piperazine H3, H5, J¼ 4 Hz); 3.05–2.98
(m, 2H, –CH2–); 3.28 (t, 4H, piperazine H2, H6, J¼ 4 Hz); 4.38
(s, 1H, (Ar)2CH–); 6.42 (t, 1H, CONH, J¼ 5.2 Hz); 7.11–7.15
(m, 4H, diphenyl H2, H6, H20, H60); 7.42–7.45 (m, 4H, diphenyl
H3, H5, H30, H50).
13C-NMR (DMSO, ppm); 16.26 (C20); 35.44
(C19); 44.03 (C14,16); 51.84 (C15,17); 73.48 (C7); 115.91–116.12
(C3,5,10,12); 130.03–130.12 (C2,6,9,13); 139.20, 139.17 (C1,8);































157.96–160.52 (C4,11); 162.95 (C18). MS (m/z); 360.85 (M
þ);
203.53 (100%, (4-F-C6H5)2CHeþ). Elemental analysis of
C20H23F2N3O (MW: 359.41 g/mol); C 66.84, H 6.45, N 11.69
(Calcd.); C 66.44, H 6.28, N 11.68 (Found).
N-Isopropyl-4-[bis(4-fluorophenyl)methyl]piperazine-1-
carboxamide (5m)
White, opaque, powdered crystals, 92% (0.345 g), m.p. 169.9 C.
UV (MeOH, max, nm); 205 (log ": 5.25), 223 (log ": 4.47). FT-IR
(KBr, cm1); 3331 (N–H), 3074 (C–H, aromatic), 2976 (C–H,
aliphatic), 1615 (C¼O, amide), 1547 (C¼C, aromatic), 1252
(C–N), 1215 (C–F). 1H-NMR (DMSO, ppm); 1.01 (d, 6H,
–CH(CH3)2, J¼ 6.8 Hz); 2.21 (t, 4H, piperazine H3, H5,
J¼ 4.4 Hz); 3.28 (t, 4H, piperazine H2, H6, J¼ 4.4 Hz); 3.68–
3.76 (m, 1H, –CH(CH3)2); 4.38 (s, 1H, (Ar)2CH–); 6.10 (d, 1H,
CONH, J¼ 7.6 Hz); 7.11–7.15 (m, 4H, diphenyl H2, H6, H20, H60);
7.42–7.45 (m, 4H, diphenyl H3, H5, H30, H50). MS (m/z); 374.87
(Mþ); 289.72 ((4-F-C6H5)2CHN(C2H4)2NHeþ); 203.54 (100%,
(4-F-C6H5)2CHeþ). Elemental analysis of C21H25F2N3O (MW:
373.44 g/mol); C 67.54, H 6.75, N 11.25 (Calcd.); C 67.87,
H 6.64, N 11.20 (Found).
Ethyl 2-[bis(4-fluorophenyl)methyl]piperazino]
carbamoylacetate (5n)
White, opaque, powdered crystals, 20% (0.08 g), m.p. 152.3 C.
UV (MeOH, max, nm); 203 (log ": 4.89), 221 (log ": 4.29). FT-IR
(KBr, cm1); 3359 (N–H), 3070 (C–H, aromatic), 2978 (C–H,
aliphatic), 1748 (C¼O, ester), 1640 (C¼O, amide), 1602 (C¼C,
aromatic), 1224 (C–O), 1198 (C–N), 1153 (C–F). 1H-NMR
(DMSO, ppm); 1.17 (t, 3H, –CH3, J¼ 7.2 Hz); 2.23 (t, 4H,
piperazine H3, H5, J¼ 5.2 Hz); 3.11 (t, 4H, piperazine H2, H6,
J¼ 4.8 Hz); 3.68 (d, 2H, –NH–CH2–, J¼ 6 Hz); 4.03–4.08 (q, 2H,
–O–CH2–); 4.39 (s, 1H, (Ar)2CH–); 6.93 (t, 1H, CONH,
J¼ 6 Hz); 7.11–7.16 (m, 4H, diphenyl H2, H6, H20, H60); 7.42–
7.46 (m, 4H, diphenyl H3, H5, H30, H50). Elemental analysis of
C22H25F2N3O3 (MW: 417.45 g/mol); C 63.30, H 6.04, N 10.07
(Calcd.); C 63.46, H 6.05, N 10.02 (Found).
N-(4-Bromophenyl)-4-[bis(4-fluorophenyl)methyl]piperazine-1-
carboxamide (5o)
White, opaque, powdered crystals, 67% (0.325 g), m.p. 210.9 C.
UV (MeOH, max, nm); 202 (log ": 4.31), 237 (log ": 4.15) , 246
(log ": 4.12). FT-IR (KBr, cm1); 3290 (N–H), 3044 (C–H,
aromatic), 2999 (C–H, aliphatic), 1646 (C¼O, amide), 1506
(C¼C, aromatic), 1246 (C–N), 1224 (C–F). 1H-NMR (DMSO,
ppm); 2.29 (t, 4H, piperazine H3, H5, J¼ 4.4 Hz); 3.45 (t, 4H,
piperazine H2, H6, J¼ 4.8 Hz); 4.44 (s, 1H, (Ar)2CH–); 7.12–7.47
(m, 12H, aromatic H’s); 8.61 (s, 1H, CONH). Elemental analysis
of C24H23BrClN3O (MW: 484.82 g/mol); C 59.27, H 4.56, N 8.64
(Calcd.); C 59.02, H 4.38, N 8.73 (Found).
N-sec-Butyl-4-[(4-chlorophenyl)(phenyl)methyl]piperazine-1-
carboxamide (5p)
White, shiny, clustered crystals, 62% (0.240 g), m.p. above
300 C. UV (MeOH, max, nm); 207 (log ": 5.32), 226 (log ":
4.51). FT-IR (KBr, cm1); 3393 (N–H), 3027 (C–H, aromatic),
2970 (C–H, aliphatic), 1618 (C¼O, amide), 1533 (C¼C,
aromatic), 1246 (C–N), 1091 (C–Cl). 1H-NMR (DMSO, ppm);
0.78 (t, 3H, –CH2–CH3, J¼ 7.6 Hz); 1.00 (d, 3H, –CH–CH3,
J¼ 6.8 Hz); 1.32–1.40 (m, 2H, –CH–CH2–CH3); 2.22 (t, 4H,
piperazine H3, H5, J¼ 4.4 Hz); 3.28 (t, 4H, piperazine H2, H6,
J¼ 4.4 Hz); 3.51–3.55 (m, 1H, –NHCH); 4.35 (s, 1H, (Ar)2CH–);
6.03 (d, 1H, CONH, J¼ 8 Hz); 7.18–7.46 (m, 9H, diphenyl).
Elemental analysis of C22H28ClN3O (MW: 385.93 g/mol);




White, shiny, flat crystals, 36% (0.137 g), m.p .190.3 C. UV
(MeOH, max, nm); 207 (log ": 5.29), 225 (log ": 4.52). FT-IR
(KBr, cm1); 3371 (N–H), 3027 (C–H, aromatic), 2968 (C–H,
aliphatic), 1629 (C¼O, amide), 1538 (C¼C, aromatic), 1257
(C–N), 1092 (C–Cl). 1H-NMR (DMSO, ppm); 1.19 (s, 9H,
–C(CH3)3); 2.19 (t, 4H, piperazine H3, H5, J¼ 4.8 Hz); 3.21
(t, 4H, piperazine H2, H6, J¼ 4.8 Hz); 4.31 (s, 1H, (Ar)2CH–);
5.65 (s, 1H, CONH); 7.17–7.42 (m, 9H, diphenyl). Elemental
analysis of C22H28ClN3O (MW: 385.93 g/mol); C 68.47, H 7.31,
N 10.89 (Calcd.); C 68.67, H 7.23, N 10.93 (Found).
N-Ethyl-4-[(4-chlorophenyl)(phenyl)methyl]piperazine-1-
carboxamide (5r)
White, shiny, clustered crystals, 17% (0.06 g), m.p. 288.6 C. UV
(MeOH, max, nm); 205 (log ": 5.24), 224 (log ": 4.46). FT-IR
(KBr, cm1); 3363 (N–H), 3020 (C–H, aromatic), 2970 (C–H,
aliphatic), 1620 (C¼O, amide), 1539 (C¼C, aromatic), 1254
(C–N), 1090 (C–Cl). 1H-NMR (DMSO, ppm); 0.98 (t, 3H, –CH3,
J¼ 7.2 Hz); 2.22 (t, 4H, piperazine H3, H5, J¼ 4.4 Hz); 3.00–3.03
(m, 2H, –CH2–); 3.27 (t, 4H, piperazine H2, H6, J¼ 5.2 Hz); 4.34
(s, 1H, (Ar)2CH–); 6.41 (t, 1H, CONH, J¼ 5.6 Hz); 7.18–7.46 (m,
9H, diphenyl). Elemental analysis of C20H24ClN3O (MW:
357.88 g/mol); C 67.12, H 6.76, N 11.74 (Calcd.); C 67.22,
H 6.69, N 11.79 (Found).
N-Isopropyl-4-[(4-chlorophenyl)(phenyl)methyl]piperazine-1-
carboxamide (5s)
White, shiny, flat crystals, 34% (0.128 g), m.p. 198.6 C. UV
(MeOH, max, nm); 205 (log ": 5.15), 223 (log ": 4.45). FT-IR
(KBr, cm1); 3390 (N–H), 3020 (C–H, aromatic), 2969 (C–H,
aliphatic), 1617 (C¼O, amide), 1532 (C¼C, aromatic), 1252
(C–N), 1092 (C–Cl). 1H-NMR (DMSO, ppm); 1.01 (d, 6H,
–CH(CH3)2, J¼ 6.8 Hz); 2.22 (t, 4H, piperazine H3, H5,
J¼ 4.4 Hz); 3.27 (t, 4H, piperazine H2, H6, J¼ 5.2 Hz); 3.68–
3.75 (m, 1H, –CH(CH3)2); 4.34 (s, 1H, (Ar)2CH–); 6.08 (d, 1H,
CONH, J¼ 7.6 Hz); 7.18–7.46 (m, 9H, diphenyl). Elemental
analysis of C21H26ClN3O (MW: 371,9 g/mol); C 67.82, H 7.05,
N 11.30 (Calcd.); C 67.88, H 7.11, N 11.35 (Found).
N-Allyl-4-[(4-chlorophenyl)(phenyl)methyl]piperazine-1-
carboxamide (5t)
White, opaque, powdered crystals, 27% (0.1 g), m.p. 172.7 C. UV
(MeOH, max, nm); 204 (log ": 5.11), 225 (log ": 4.38). FT-IR
(KBr, cm1); 3356 (N–H), 3027 (C–H, aromatic), 2981 (C–H,
aliphatic), 1622 (C¼O, amide), 1543 (C¼C, aromatic), 1252
(C–N), 1094 (C–Cl). 1H-NMR (DMSO, ppm); 2.23 (t, 4H,
piperazine H3, H5, J¼ 4.8 Hz); 3.30 (t, 4H, piperazine H2, H6,
J¼ 4.8 Hz); 3.63 (t, 2H, NH–CH2–CH¼, J¼ 4.8 Hz); 4.34 (s, 1H,
(Ar)2CH–); 4.97–5.08 (dd, 2H, –CH¼CH2, J1¼ 16 Hz,
J2¼ 10 Hz, J3¼ 1.6 Hz); 5.75–5.82 (m, 1H, –CH¼CH2); 6.62
(t, 1H, CONH); 7.18–7.46 (m, 9H, diphenyl). Elemental analysis
of C21H24ClN3O (MW: 371.9 g/mol); C 68.19, H 6.54, N 11.36
(Calcd.); C 68.52, H 6.43, N 11.43 (Found).
N-(2,6-Dichlorophenyl)-4-[(4-chlorophenyl)(phenyl)methyl]
piperazine-1-carboxamide (5u)
White, shiny, powdered crystals, 38% (0.178 g), m.p. 224.6 C.
UV (MeOH, max, nm); 205 (log ": 4.47), 245 (log ": 4.12).































FT-IR (KBr, cm1); 3316 (N–H), 3020 (C–H, aromatic), 2963
(C–H, aliphatic), 1645 (C¼O, amide), 1519 (C¼C, aromatic),
1254 (C–N), 1089 (C–Cl). 1H-NMR (DMSO, ppm); 2.31 (t, 4H,
piperazine H3, H5, J¼ 4.8 Hz); 3.46 (t, 4H, piperazine H2, H6,
J¼ 4.4 Hz); 4.41 (s, 1H, (Ar)2CH–); 7.21–7.49 (m, 12H, aromatic
H’s); 8.37 (s, 1H, CONH). Elemental analysis of C24H22Cl3N3O
(MW: 474.81 g/mol); C 60.71, H 4.67, N 8.85 (Calcd.); C 60.70,
H 4.77, N 9.18 (Found).
N-(2-Phenylethyl)-4-[(4-chlorophenyl)(phenyl)methyl]piperazine-
1-carboxamide (5v)
White, opaque, feather-like crystals, 49% (0.212 g), m.p. 147.8 C.
UV (MeOH, max, nm); 205 (log ": 4.52), 245 (log ": 4.07). FT-IR
(KBr, cm1); 3307 (N–H), 3022 (C–H, aromatic), 2955 (C–H,
aliphatic), 1617 (C¼O, amide), 1543 (C¼C, aromatic), 1256
(C–N), 1091 (C–Cl). 1H-NMR (DMSO, ppm); 2.22 (t, 4H,
piperazine H3, H5, J¼ 4.4 Hz); 2.69 (t, 2H, –CH2–C6H5,
J¼ 6.8 Hz); 3.19 (q, 2H, –NHCH2); 3.28 (t, 4H, piperazine H2,
H6, J¼ 5.2 Hz); 4.34 (s, 1H, (Ar)2CH–); 6.55 (t, 1H, CONH,
J¼ 5.6 Hz); 7.15–7.46 (m, 14H, aromatic H’s). Elemental analysis
of C26H28ClN3O (MW: 433.97 g/mol); C 71.96, H 6.50, N 9.68
(Calcd.); C 72.04, H 6.72, N 9.70 (Found).
N-(4-Bromophenyl)-4-[(4-chlorophenyl)(phenyl)methyl]
piperazine-1-carboxamide (5w)
White, opaque, feather-like crystals, 37% (0.180 g), m.p. 195.5 C.
UV (MeOH, max, nm); 203 (log ": 4.33), 236 (log ": 4.11). FT-IR
(KBr, cm1); 3316 (N–H), 3028 (C–H, aromatic), 2966 (C–H,
aliphatic), 1634 (C¼O, amide), 1537 (C¼C, aromatic), 1243
(C–N), 1089 (C–Cl). 1H-NMR (DMSO, ppm); 2.30 (t, 4H,
piperazine H3, H5, J¼ 4.8 Hz); 3.45 (t, 4H, piperazine H2, H6,
J¼ 4.8 Hz); 4.39 (s, 1H, (Ar)2CH–); 7.21–7.47 (m, 13H, aromatic
H’s); 8.6 (s, 1H, CONH). Elemental analysis of C24H23BrClN3O
(MW: 484.82 g/mol); C 59.46, H 4.78, N 8.67 (Calcd.); C 59.43,
H 4.97, N 8.84 (Found).
N-(2-Benzylphenyl)-4-[(4-chlorophenyl)(phenyl)methyl]
piperazine-1-carboxamide (5x)
White, shiny, needle-shaped crystals, 44% (0.219 g), m.p.
174.6 C. UV (MeOH, max, nm); 205 (log ": 4.57), 224 (log ":
4.21). FT-IR (KBr, cm1); 3332 (N–H), 3026 (C–H, aromatic),
2967 (C–H, aliphatic), 1626 (C¼O, amide), 1523 (C¼C,
aromatic), 1251 (C–N), 1089 (C–Cl). 1H-NMR (DMSO, ppm);
2.23 (bs, 4H, piperazine H3, H5); 3.36 (bs, 4H, piperazine H2, H6);
3.91 (s, 2H, –CH2–); 4.34 (s, 1H, (Ar)2CH–); 7.05–7.47 (m, 18H,
aromatic H’s); 7.96 (s, 1H, CONH). 13C-NMR (DMSO, ppm);
37.74 (C25); 44.46 (C14,16); 51.91 (C15,17); 74.48 (C7); 125.46
(C20); 126.52 (C22); 126.97 (C29); 127.23 (C21); 127.79 (C27,31);
128.31 (C11); 128.91 (C9,13); 129.23 (C23); 129.33 (C28,30);
129.42 (C10,12); 130.11 (C3,5); 130.64 (C2,6); 132.09 (C4); 136.87
(C19); 138.23 (C1); 141.05 (C26); 142.26 (C8); 142.64 (C24);
156.06 (C18). MS (m/z); 496.9 (M
þ, 100%); 498.9 (Mþ 2, 33%);
287.8 ((4-Cl-C6H5)(C6H5)CH-N(C2H4)2Neþ); 201.6 ((4-Cl-
C6H5)(C6H5)CHeþ). Elemental analysis of C31H30ClN3O (MW:




White, shiny, powdered crystals, 26% (0.114 g), m.p. 196.8 C.
UV (MeOH, max, nm); 202 (log ": 4.82), 270 (log ": 4.59). FT-IR
(KBr, cm1); 3278 (N–H), 3027 (C–H, aromatic), 2951 (C–H,
aliphatic), 2221 (CN), 1653 (C¼O, amide), 1513 (C¼C,
aromatic), 1245 (C–N), 1089 (C–Cl). 1H-NMR (DMSO, ppm);
2.32 (t, 4H, piperazine H3, H5, J¼ 4.8 Hz); 3.48 (t, 4H, piperazine
H2, H6, J¼ 4.8 Hz); 4.41 (s, 1H, (Ar)2CH–); 7.21–7.47
(m, 9H, diphenyl); 7.61–7.67 (m, 4H, 4-cyanophenyl); 8.97
(s, 1H, CONH). Elemental analysis of C25H23ClN4O (MW:
430.93 g/mol); C 69.68, H 5.38, N 13.00 (Calcd.); C 69.74,
H 5.50, N 13.06 (Found).
General procedure for preparation of N-Alkyl-4-
[4-chlorobenzhydryl/4,40-difluorobenzhydryl]piperazine-
1-carbothioamides
A total of 1.7 mmol (0.515 g) 1-[Bis(4-fluorophenyl)methyl]
piperazine or 0.872 mmol (1 mol, 0.2632 g) 1-[(4-chlorophenyl)
(phenyl)methyl]piperazine was dissolved in 20 ml dry dichlor-
omethane. Reaction flask was taken into ice bath and triethyla-
mine (1:3 moles) was added to the solution. After 10 min, ice bath
was removed and suitable isothiocyanate derivative (1:1 mole)
was added. Reaction was stirred overnight at room temperature.
After the reaction was completed, solution was extracted in
order with water and ammonium chloride solution (10%).
Dichloromethane layer was washed with water again and dried
with anhydrous sodium sulfate. Solvent was evaporated under
vacuo and solid product was recrystallized with ethanol/water.
N-tert-Butyl-4-[bis(4-fluorophenyl)methyl]piperazine-1-
carbothioamide hydrochloride (6a)
Yellowish white, opaque, powdered crystals, 14% (0.06 g), m.p.
176.8 C. UV (MeOH, max, nm); 205 (log ": 4.23), 223 (log ":
4.11). FT-IR (KBr, cm1); 3258 (N–H), 3057 (C–H, aromatic),
2972 (C–H, aliphatic), 1606 (C¼C, aromatic), 1288 (C–N), 1236
(C¼S, thioamide), 1189 (C–F). 1H-NMR (DMSO, ppm); 1.45
(s, 9H, –C(CH3)3); 2.96–3.15 (m, 4H, piperazine H3, H5); 3.65
(t, 4H, piperazine H2, H6); 4.59 (d, 1H, (Ar)2CH–, J¼ 14.4 Hz);
5.75 (d, 1H, CSNH, J¼ 8.8 Hz); 7.17–7.33 (m, 4H, diphenyl H2,
H6, H20, H60); 7.95 (bs, 4H, diphenyl H3, H5, H30, H50); 12.55
(bs, 1H, N–H salt). MS (m/z); 404.90 (100%, Mþ – Cl); 205.3
((4-F-C6H5)2CHeþ). Elemental analysis of C22H28ClF2N3S (MW:
439.99 g/mol); C 60.05, H 6.41, N 9.55, S 7.29 (Calcd.); C 59.55,
H 6.45, N 9.47, S 6.64 (Found).
N-Cyclohexyl-4-[bis(4-fluorophenyl)methyl]piperazine-1-
carbothioamide (6b)
White, shiny, needle-shaped crystals 50%, (0.214 g), m.p.
198.2 C. UV (MeOH, max, nm); 202 (log ": 4.10), 224 (log ":
4.02), 248 (log ": 3.88). FT-IR (KBr, cm1); 3328 (N–H), 3060
(C–H, aromatic), 2996 (C–H, aliphatic), 1603 (C¼C, aromatic),
1299 (C–N), 1221 (C¼S, thioamide), 1104 (C–F). 1H-NMR
(DMSO, ppm); 1.13–1.21 (m, 5H, cyclohexyl); 1.53–1.79 (m, 6H,
cyclohexyl); 2.22 (t, 4H, piperazine H3, H5, J¼ 4.8 Hz); 3.71
(t, 4H, piperazine H2, H6, J¼ 4.4 Hz); 4.12 (s, 1H, CSNH); 4.40
(s, 1H, (Ar)2CH–); 7.09–7.14 (m, 4H, diphenyl H2, H6, H20, H60);
7.39–7.43 (m, 4H, diphenyl H3, H5, H30, H50).
13C-NMR (DMSO,
ppm); 24.99 (C21,23); 25.18 (C22); 31.97 (C20,24); 47.06 (C14,16);
50.85 (C15,17); 54.28 (C19); 72.32 (C7); 115.14 (C10,12); 115.35
(C3,5); 129.35 (C9,13); 129.43 (C2,6); 138.12 (C8); 138.15 (C1);
159.79 (C11); 162.21 (C4); 180.14 (C18). MS (m/z); 430.95
(100%, Mþ); 203.65 ((4-F-C6H5)2CHeþ). Elemental analysis
of C24H29F2N3S (MW: 429.57 g/mol); C 67.10, H 6.80, N 9.78,
S 7.46 (Calcd.); C 66.94, H 6.94, N 9.89, S 7.42 (Found).
N-Ethyl-4-[(4-chlorophenyl)(phenyl)methyl]piperazine-1-
carbothioamide (6c)
White, opaque, powdered crystals, 15% (0.056 g), m.p. 150.6 C.
UV (MeOH, max, nm); 204 (log ": 4.25), 225 (log ": 4.13).
FT-IR (KBr, cm1); 3294 (N–H), 3020 (C–H, aromatic), 2966































(C–H, aliphatic), 1531 (C¼C, aromatic), 1255 (C–N), 1229
(C¼S, thioamide), 1289 (C–N), 1091 (C–Cl). 1H-NMR (DMSO,
ppm); 1.06 (t, 3H, –CH3, J¼ 6.8 Hz); 2.27 (t, 4H, piperazine
H3, H5, J¼ 5.2 Hz); 3.52–3.45 (m, 2H, –CH2–); 3.75 (t, 4H,
piperazine H2, H6, J¼ 4.8 Hz); 4.39 (s, 1H, (Ar)2CH–); 7.19–7.46
(m, 9H, diphenyl); 7.61 (t, 1H, CSNH). Elemental analysis
of C20H24ClN3S (MW: 373.94 g/mol); C 64.24, H 6.47, N 11.24,
S 8.57 (Calcd.); C 64.44, H 6.19, N 11.35, S 8.67 (Found).
N-Isopropyl-4-[(4-chlorophenyl)(phenyl)methyl]piperazine-1-
carbothioamide (6d)
White, shiny, needle-shaped crystals, 39% (0.15 g), m.p. 252.4 C.
UV (MeOH, max, nm); 203 (log ": 4.31), 223 (log ": 4.15). FT-IR
(KBr, cm1); 3371 (N–H), 3059 (C–H, aromatic), 2967 (C–H,
aliphatic), 1539 (C¼C, aromatic), 1270 (C–N), 1232 (C¼S,
thioamide), 1232 (C–N), 1001 (C–Cl). 1H-NMR (DMSO, ppm);
1.09 (d, 6H, –(CH3)2, J¼ 6.8 Hz); 2.27 (t, 4H, piperazine H3, H5,
J¼ 4.8 Hz); 3.76 (t, 4H, piperazine H2, H6, J¼ 4.8 Hz); 4.39
(s, 1H, (Ar)2CH–); 4.44–4.53 (m, 1H, –CH(CH3)2); 7.19–7.46
(m, 10H, diphenyl H’sþNH). 13C-NMR (DMSO, ppm); 38.79–
40.05 (C20,21); 46.93–47.01 (C14,15,16,17); 50.93 (C19); 73.36 (C7);
127.05 (C11); 127.57 (C9,13); 128.42 (C10,12); 128.52 (C3,5);
129.35 (C2,6); 131.32 (C4); 141.28 (C8); 141.64 (C1); 180.17
(C18). MS (m/z); 388.8 (M
þ, 100%); 390.8 (Mþ 2, 33%); 201.5
(4-Cl-C6H5)(C6H5)CH
þ). Elemental analysis of C21H26ClN3S
(MW: 387.97 g/mol); C 65.01, H 6.75, N 10.83, S 8.26
(Calcd.); C 64.88, H 6.88, N 10.87, S 8.29 (Found).
N-Allyl-4-[(4-chlorophenyl)(phenyl)methyl]piperazine-1-
carbothioamide (6e)
White, opaque, powdered crystals, 10% (0.040 g), m.p. 139.4 C.
UV (MeOH, max, nm); 204 (log ": 4.27), 225 (log ": 4.13). FT-IR
(KBr, cm1); 3296 (N–H), 3023 (C–H, aromatic), 2960 (C–H,
aliphatic), 1528 (C¼C, aromatic), 1252 (C–N), 1224 (C¼S,
thioamide), 1223 (C–N), 1090 (C–Cl). 1H-NMR (DMSO, ppm);
2.28 (t, 4H, piperazine H3, H5, J¼ 5.2 Hz); 3.79 (t, 4H, piperazine
H2, H6, J¼ 4 Hz); 4.15 (t, 2H, –CH2–CH¼CH2, J¼ 5.6 Hz); 4.39
(s, 1H, (Ar)2CH–); 5.01–5.11 (dd, 2H, –CH¼CH2, J1¼ 17.2 Hz,
J2¼ 8.6 Hz, J3¼ 1.6 Hz); 5.80–5.90 (m, 1H, –CH¼CH2);
7.19–7.46 (m, 9H, diphenyl); 7.80 (t, 1H, CSNH, J¼ 5.6 Hz).
Elemental analysis of C21H24ClN3S (MW: 385.95 g/mol);
C 65.35, H 6.27, N 10.89, S 8.31 (Calcd.); C 65.71, H 6.44,
N 11.01, S 8.28 (Found).
N-Benzyl-4-[(4-chlorophenyl)(phenyl)methyl]piperazine-1-
carbothioamide (6f)
White, opaque, featherlike crystals, 23% (0.1 g), m.p. 157.2 C.
UV (MeOH, max, nm); 203 (log ": 4.51), 226 (log ": 4.33). FT-IR
(KBr, cm1); 3236 (N–H), 3020 (C–H, aromatic), 2813 (C–H,
aliphatic), 1539 (C¼C, aromatic), 1246 (C–N), 1211 (C¼S,
thioamide), 1246 (C–N), 1001 (C–Cl). 1H–NMR (DMSO, ppm);
2.31 (t, 4H, piperazine H3, H5, J¼ 4.8 Hz); 3.83 (t, 4H, piperazine
H2, H6, J¼ 4.4 Hz); 4.41 (s, 1H, (Ar)2CH–); 4.79 (d, 2H, –CH2–,
J¼ 5.2 Hz); 7.19–7.47 (m, 14H, aromatic H’s); 8.19 (t, 1H,
CSNH, J¼ 5.6 Hz). Elemental analysis of C25H26ClN3S (MW:
436.01 g/mol); C 68.87, H 6.01, N 9.64, S 7.35 (Calcd.); C 69.02,
H 5.98, N 9.80, S 7.46 (Found).
N-Butyl-4-[(4-chlorophenyl)(phenyl)methyl]piperazine-1-
carbothioamide hydrochloride (6g)
White, opaque, feather-like crystals, 20% (0.080 g), m.p. 125.5 C.
UV (MeOH, max, nm); 204 (log ": 4.43), 227 (log ": 4.35). FT-IR
(KBr, cm1); 3261 (N–H), 3028 (C–H, aromatic), 2958
(C–H, aliphatic), 1541 (C¼C, aromatic), 1298 (C–N), 1201
(C¼S, thioamide), 1201 (C–N), 1001 (C–Cl). 1H-NMR (DMSO,
ppm); 0.87 (t, 3H, –CH2CH2CH3, J¼ 7.2 Hz); 1.20–1.29 (m, 2H,
–CH2CH2CH3); 1.44–1.52 (m, 2H, –CH2CH2CH3); 2.27 (t, 4H,
piperazine H3, H5, J¼ 4.8 Hz); 3.42–3.47 (q, 2H, –NHCH2–);
3.75 (t, 4H, piperazine H2, H6, J¼ 4.8 Hz); 4.39 (s, 1H, (Ar)2CH–
); 7.19–7.46 (m, 9H, diphenyl); 7.58 (t, 1H, CSNH, J¼ 5.6 Hz).
Elemental analysis of C22H28ClN3S (MW: 401.17 g/mol); C
65.73, H 7.02, N 10.45, S 7.98 (Calcd.); C 66.06, H 7.07, N 10.56,
S 8.05 (Found).
Cytotoxicity studies
The cytotoxic activity of the synthesized compounds was
investigated initially on liver (HUH-7), breast (MCF-7) and
colon (HCT-116) cancer cell lines, by means of SRB assays
in triplicate. Serial dilutions from 100mM to 2.5mM were used,
5-fluorouracil (5-FU) was the reference compound and camp-
tothecin (CPT) was the positive control for the cytotoxic effect.
Cell culture
The human cancer cell lines were grown in Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin. Each cell line was maintained in
an incubator at 37 C supplied with 5% CO2 and 95% air.
NCI-60 SRB assay
Cancer cells (range of 2000 cell/well to 5000 cell/well) were
inoculated into 96-well plates in 200ml of media and incubated in
37 C incubators containing 5% CO2 and 95% air. After a 24 h
incubation period, one plate for each cell line was fixed with
100ml of 10% ice-cold trichloroacetic acid (TCA). This plate
represents the behavior of the cells just prior to the drug treatment
and is accepted as the time-zero plate. The compounds to be
tested were solubilized in DMSO to a final concentration of
40 mM and stored at þ4 C. While treating the cells with the
compounds, the corresponding volume of the compound was
applied to the cell to achieve the desired drug concentration and
diluted through serial dilution. After the drug treatment, the cells
were incubated in 37 C incubators containing 5% CO2 and 95%
air for 72 h. Following the termination of the incubation period
after the drug treatment, the cells were fixed with 100 ml of 10%
ice-cold TCA and incubated in the dark at þ4 C for 1 h. Then the
TCA was washed away with ddH2O five times and the plates were
left to air dry. For the final step, the plates were stained with
100ml of 0.4% SRB solution in 1% acetic acid solution. Following
staining, the plates were incubated in dark for 10 min at room
temperature. The unbound dye was washed away using 1% acetic
acid and the plates were left to air dry. To measure the absorbance
results, the bound stain was then solubilized using 200ml of
10 mM Tris-Base. The OD values were obtained at 515 nm.
Results and discussion
Chemistry
The synthesis of the benzhydrylpiperazine derivatives (5a–y)
and (6a–g) is outlined in Figure 1. Reduction with sodium
borohydride of benzophenone, 4-chlorobenzophenone and 4,40-
difluorobenzophenone afforded benzhydrole derivatives which
were chlorinated with HCl and anhydrous calcium chloride.
Resulting benzhydryl chloride derivatives were used for
N-alkylation of piperazine to give 1-benzhydrylpiperazine,
4-chlorobenzhydrylpiperazine and 4,40-difluorobenzhydrylpiper-
azine. The final step was nucleophilic addition to isocyanates
or isothiocyanates in order to obtain benzhydrylpiperazine
derivatives (5a–y) and (6a–g).































Synthesized compounds were identified with IR, UV and
1H-NMR spectra. In addition, some compounds were selected
for LC-MS and 13C-NMR spectral evaluation. In UV spectra
of carboxamide derivatives there are two significant bands at 205
and 224 nm, which represent !* and n!* transitions.
In UV spectra of thioamide derivatives there are three significant
bands nearly at 202, 224 and 248 nm, which represent !*
and n!* transitions. In IR spectrum of carboxamide deriva-
tives, characteristic N–H stretching band is observed nearly at
3332 cm1. Other stretching bands are observed approximately
at 3020 cm1 (C–H; aromatic), 2965 cm1 (C–H; aliphatic),
1625 cm1 (C¼O; amide), 1520 cm1 (C¼C; aromatic) and
1250 cm1 (C–N). In IR spectrum of thioamide derivatives,
characteristic N–H stretching band is observed nearly at
3330 cm1. Other stretching bands are observed approximately
at 3060 cm1 (C–H; aromatic), 2995 cm1 (C–H; aliphatic),
1600 cm1 (C¼C; aromatic), 1300 cm1 (C–N) and 1220 cm1
(C¼S) and 1100 cm1 (C–F). In H1-NMR spectra of carboxamide
derivatives the protons of piperazine are seen approximately
at 2.23 and 3.36 ppm as broad singlets. Diphenylmethyl C–H
gives a singlet nearly at 4 ppm. Aromatic rings give multiplets
at 7–7.5 ppm. Amide N–H gives a singlet nearly at 8 ppm.
In H1-NMR spectra of thioamide derivatives, the protons
of piperazine are seen at 2.5 (t, 4H, J¼ 5.2 Hz) ppm and 3.5
(t, 4H, H1, J¼ 4 Hz) ppm approximately. Diphenylmethyl C–H
gives a singlet nearly at 4.5 ppm. Protons of aromatic rings
give multiplets at 7–7.5 ppm. Thioamide N–H is observed
approximately at 7.5 ppm. The 13C-NMR spectrum of 5x
shows characteristic peaks of the carboxamide derivatives
approximately at 45 and 50 ppm for piperazine ring, 75 ppm
for diphenylmethyl carbon and 150 ppm for carbonyl group. The
13C-NMR spectrum of 6b shows characteristic peaks of the
thioamide derivatives nearly at 45 and 50 ppm for piperazine ring,
70 ppm for diphenylmethyl carbon and 180 ppm for thiocarbonyl
group.
Structures of the prepared benzhydrylpiperazine derivatives
are illustrated in Table 1.
Cytotoxicity
The cytotoxic activity of the synthesized compounds 5a–y and
6a–g was investigated on liver (HUH-7), breast (MCF-7) and
colon (HCT-116) cancer cell lines, by means of SRB assays
in triplicate. As shown in Table 2, all tested compounds were
screened with mean 50% growth inhibition concentration (GI50)
in micromolar concentration range.
Most of the nonsubstituted benzhydrylpiperazine derivatives





























a. isocyanates, TEA, DCM, b. isothiocyanates, TEA, DCM
Figure 1. Synthesis of compounds 5a–y and 6a–g.































cell lines. It should also be noted that, in general, 4-chlorobenz-
hydrylpiperazine derivatives have higher activities becoming
superior over their 4,40-difluoro and nonsubstituted counterparts.
Moreover, thioamide derivatives are more potent than carbox-
amide derivatives against all cancer cell lines. Corresponding
compound groups representing these findings are detailed in
Table 3.
Compounds 5c, 5m, 5s and 6d have the same substituents
on NH group (R3¼ isopropyl). Compound 5c has no cytotoxicity
against any of these cancer cell lines. However, 5m has slight
cytotoxicity, 5s has good cytotoxicity and 6d has the highest
cytotoxicity against all three cancer cell lines.
Compounds 5e and 5u have the same substituents on NH group
(R3¼ 2,6-dichlorophenyl). 5e has no cytotoxicity against any of
the cancer cell lines. Interestingly, 5u has increased cytotoxicity
against all the cancer cell lines.
Compounds 5f and 5x have the same substituents on NH group
(R3¼ 2-benzylphenyl). 5f has no cytotoxicity against none of
these cancer cell lines. However, 5x has good cytotoxicity against
all the cancer cell lines.
Compounds 5h, 5t and 6e have the same substituents on
NH group (R3¼ allyl). 5h has no cytotoxicity against HUH-7 and
HCT-116 cell lines nevertheless it has good cytotoxicity against
MCF-7 cell line. However, 5t has elevated cytotoxicity and 6e has
the highest cytotoxicity against all three cancer cell lines.
In general, nonsubstituted benzhydryl derivatives are inactive
or have low inhibition whereas 4-chlorobenzhydryl derivatives are
more active than other compounds against HUH-7 cell line.
The most active compounds against HUH-7 cell line are 5y
(GI50¼ 1.29 mM) and 6a (GI50¼ 5.97 mM). Additionally, most
of the compounds have higher cytotoxicity against HUH-7 than
reference compound 5-fluorouracil.
Among the carboxamide derivatives, compounds bearing
electron withdrawing substituents on phenyl ring such as 5o
(GI50¼ 9.46 mM), 5u (GI50¼ 6.44 mM), 5w (GI50¼ 8.54 mM)
and 5y (GI50¼ 1.29 mM) are highly active against HUH-7 cell
line. In addition, alkyl substituted derivatives, except thioamide
derivatives, have no (5a–d, 5h, 5n) or low inhibition (5i–m, 5p–t).
Thioamide derivatives are generally cytotoxic against
HUH-7 cell line. It can be noted that thioamides show higher
activity than their carboxamide derivatives, which can be
exemplified by compounds 5j (GI50¼ 29.96mM) compared
with 6a (GI50¼ 5.97 mM), 5r (GI50¼ 20.92 mM) compared with
6c (GI50¼ 10.81mM), 5s (GI50¼ 15.36mM) compared with 6d
(GI50¼ 6.20 mM) and 5t (GI50¼ 16.29 mM) compared with 6e
(GI50¼ 9.95 mM).













5a* O - H - H sec-Butyl 198.4 68
5b O - H - H tert-Butyl 192.4 62
5c O - H - H Isopropyl 220.4 94
5d O - H - H Ethyl 208.9 84
5e O - H - H 2,6-Dichlorophenyl 234.6 88
5f O - H - H 2-Benzylphenyl 192.1 89
5g* O - H - H Ethylacetato 150.0 69
5h* O - H - H Allyl 213.6 96
5i O - F - F sec-Butyl 157.7 54
5j O - F - F tert-Butyl 162.4 82
5k O - F - F Butyl 132.9 45
5l O - F - F Ethyl 175 83
5m O - F - F Isopropyl 169.9 92
5n O - F - F Ethylacetato 152.3 20
5o O - F - F 4-Bromophenyl 210.9 67
5p O - Cl - H sec-Butyl 4300 (dec.) 62
5q O - Cl - H tert-Butyl 190.3 36
5r O - Cl - H Ethyl 288.6 (dec.) 17
5s O - Cl - H Isopropyl 198.6 34
5t O - Cl - H Allyl 172.7 27
5u O - Cl - H 2,6-Dichlorophenyl 224.6 38
5v O - Cl - H 2-Phenylethyl 147.8 49
5w O - Cl - H 4-Bromophenyl 195.5 37
5x O - Cl - H 2-Benzylphenyl 174.6 44
5y O - Cl - H 4-Cyanophenyl 196.8 26
6a S - F - F tert-Butyl 176.8 14
6b S - F - F Cyclohexyl 198.2 50
6c S - Cl - H Ethyl 150.6 15
6d S - Cl - H Isopropyl 252.4 (dec.) 39
6e S - Cl - H Allyl 139.4 10
6f S - Cl - H Benzyl 157.2 23
6g S - Cl - H Butyl 125.5 20
(*) 5a, CAS No: 1071382-92-7; 5g, CAS No: 1350123-57-7; 5h, CAS
No: 1349487-56-4.
Table 2. Cytotoxic activity data for compounds 5a–y and 6a–g.
Cancer cell line GI50 (mM)
Sample HUH-7 R2 MCF-7 R2 HCT-116 R2
5a NI* – NI – NI –
5b NI – NI – 1.01 0.78
5c NI – NI – NI –
5d NI – 25.7 0.86 NI –
5e NI – NI – NI –
5f NI – NI – NI –
5g NI – NI – NI –
5h NI – 10.91 0.78 NI –
5i 13.85 0.94 NI 0.79 24.48 0.77
5j 29.96 0.88 NI 0.77 28.4 0.85
5k 13.39 0.91 19.03 0.84 16.24 0.86
5l 34.84 0.79 NI 0.64 17.98 0.88
5m 36.57 0.79 45.23 0.76 20.94 0.91
5n NI – 36.14 0.55 NI –
5o 9.46 0.98 8.68 0.85 8.87 0.97
5p 13.03 0.98 11.39 0.71 9.33 0.95
5q 10.88 0.93 8.77 0.98 9.33 0.94
5r 20.92 0.92 60.24 0.24 10.78 0.99
5s 15.36 0.86 13.16 0.74 17.12 0.95
5t 16.29 0.96 9.12 0.77 10.14 0.99
5u 6.44 0.97 6.14 0.93 8.93 0.96
5v 13.18 0.97 8.51 0.93 5.72 0.98
5w 8.54 0.94 9.28 0.92 7.34 0.99
5x 17.22 0.74 16.91 0.71 4.76 0.98
5y 1.29 0.88 6.34 0.92 1.81 0.99
6a 5.97 0.87 10.62 0.91 13.09 0.86
6b 25.8 0.98 NI 0.83 NI 0.67
6c 10.81 0.66 NI – 13.75 0.91
6d 6.20 0.86 11.47 0.89 14.98 0.84
6e 9.95 0.93 4.94 0.82 8.85 0.98
6f 22.59 0.81 23.00 0.59 12.68 0.89
6g 8.10 0.93 14.80 0.88 13.91 0.79
5-FU 30.66 0.98 3.51 0.96 18.67 0.98
CPT 0.15 0.89 50.1 0.87 50.1 0.91
(*): Compounds active above 100 mM concentration were considered to
have no inhibition.































The most active compounds against MCF-7 cell line are 5u
(GI50¼ 6.14 mM) and 6e (GI50¼ 4.94 mM). Furthermore, we
observed that compound 6e was less toxic in MCF-12A
(GI50¼ 8.5 mM), which is a normal-like breast epithelial cell
line (Table 4).
Against MCF-7 cell line, nonsubstituted benzhydryl carbox-
amide derivatives (except 5d and 5h) and 5i, 5j, 5l, 6b, 6c show
no inhibition. Alkyl-substituted carboxamide derivatives have
low activity values such as 5d (GI50¼ 25.7 mM), 5k (GI50¼
19.03mM), 5m (GI50¼ 45.23mM), 5n (GI50¼ 36.14mM),
5r (GI50¼ 60.24 mM). However, compounds such as 5u
(GI50¼ 6.14 mM) and 5y (GI50¼ 6.34 mM) that contain phenyl
ring with electron withdrawing substituents are highly cytotoxic.
Against HCT-116 cell line, 5b (GI50¼ 1.01 mM) and 5y
(GI50¼ 1.81 mM) are the most active derivatives. In addition,
most of the compounds have higher cytotoxicity against HCT-116
than reference compound 5-fluorouracil.
With the exception of 5b, nonsubstituted benzhydryl carbox-
amide derivatives present no inhibition against HCT-116 cell
line. 4-Chlorobenzhydryl carboxamide derivatives are higher
in activity than 4,40-difluorobenzhydryl carboxamide derivatives
demonstrated with compounds 5i (GI50¼ 24.48mM) and 5p
(GI50¼ 9.33 mM) or compounds 5j (GI50¼ 28.4 mM) and 5q
(GI50¼ 9.33 mM). Thioamides generally show good activity
values considering HCT-116 cell line.
Conclusion
In this study, 32 benzhydrylpiperazine derivatives with carbox-
amide and thioamide moieties were prepared. In vitro cytotoxic
activities were screened against hepatocellular (HUH-7),
breast (MCF-7) and colorectal (HCT-116) cancer cell lines by
SRB assay. Most of the compounds presented higher cyto-
toxicity against HUH-7 and HCT-116 cancer cell lines in com-
parison with reference compound 5-fluorouracil. Interestingly,
4-chlorobenzhydrylpiperazine derivatives were more active than
benzhydrylpiperazine and 4,40-difluorobenzhydrylpiperazine
derivatives. In addition, thioamide derivatives were observed to
have markedly elevated cytotoxicity values opposed to their
carboxamide analogs. Future synthesis of similar derivatives will
take place to create a larger set of compounds, in order to produce
a rational quantitative structure-activity relationship (QSAR)
mapping. Since 4-chlorobenzhydrylpiperazine derivatives are
chiral compounds, further exploration of chiral separation
methods will be performed. The primary ambition regarding
future research is to evaluate the mechanism of cytotoxicity.
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